BKT

Biokine Therapeutics is an Israeli clinical-stage biopharmaceutical company focused on oncology and inflammation, with a historical emphasis on the tumor microenvironment and chemokine biology. The company is best known for discovering BKT-140, later licensed to BioLineRx as BL-8040 (motixafortide), a CXCR4 antagonist that advanced into mid- to late-stage clinical development outside Biokine. Beyond its lead chemistry, Biokine has described additional internal preclinical programs including BKT-130, BKT-170, BKT-104, BKT-RP3, and BKT-300, largely centered on chemokine signaling or related pathway modulation. The company also reports proprietary discovery platforms including ChemoHit, Peptein, and ReceptorHit for identifying antagonists and agonists in chemokine and GPCR-related pathways. Overall, Biokine appears to be a small private biotech with a platform-enabled discovery model and a legacy asset base in oncology, inflammation, and tissue injury.